CDSCO Raises Red Flag Over Unauthorised Sale Of Anti-Obesity Drugs

Expressing concerns over the growing misuse, unauthorised sale, and misleading promotion of GLP-1-based weight-loss medications, the Central Drugs Standard Control Organisation (CDSCO) has warned States and Union Territories against possible leakage of these drugs into unregulated channels.

The latest warning comes months after the top drug regulator issued a comprehensive advisory in March directing drug manufacturers to stop misleading advertisements or promotional material that could encourage the use of GLP-1 drugs without prescription-based medical supervision.

The CDSCO has now directed State drug controllers to intensify surveillance across the entire supply chain of GLP-1 drugs and initiate strict action against illegal distribution, unethical promotion, and dispensing practices that violate approved medical guidelines.

The move follows increasing concerns over the easy availability of these medicines through online pharmacies, wellness clinics, slimming centres, and retail outlets, often without adequate medical supervision.

In a communication to State Licensing Authorities (SLAs), Rajeev Singh Raghuvanshi said that the CDSCO, along with State regulators, had already initiated nationwide inspections and enforcement drives targeting online pharmacy warehouses, wholesalers, retail chemists, and wellness clinics.

“Over the past several weeks, CDSCO, in coordination with State Licensing Authorities, has undertaken a nationwide enforcement drive to curb illegal distribution channels, non-compliant dispensing practices, and misuse of GLP-1-based weight-loss drugs,” he stated.

The regulator revealed that notices had already been issued to entities found violating conditions related to the manufacture, sale, and promotional practices associated with these drugs.

The CDSCO has now asked States to ensure strict monitoring of the end-to-end movement of GLP-1 drugs — from import and manufacture to wholesale distribution, retail dispensing, and final patient use.

The regulator warned that any diversion of the medicines into unauthorised channels, promotional practices influencing irrational use, or violation of approved indications should be treated seriously and attract regulatory action.

A section of medical experts has repeatedly warned that the medicines are not risk-free and require careful medical supervision.

The government has cautioned that these drugs may cause adverse effects ranging from nausea, vomiting, and dehydration to more serious complications such as pancreatitis, bowel obstruction, and kidney injury.

Health experts fear that increasing social media-driven demand for rapid weight loss, celebrity endorsements, and aggressive digital marketing may be fuelling irrational use among otherwise healthy individuals seeking cosmetic weight reduction.

The CDSCO has specifically instructed States to monitor print, electronic, digital, and social media platforms for misleading advertisements and surrogate promotional activities related to these drugs.

The regulator also reminded States to enforce provisions under the Drugs and Magic Remedies (Objectionable Advertisements) Act and the Drugs and Cosmetics Act against manufacturers, marketers, importers, and other entities found violating advertising regulations.

Doctors have also warned that unsupervised use may become especially dangerous among individuals with pre-existing gastrointestinal, pancreatic, or renal disorders.

They said the regulator’s intervention reflects growing concern that India may witness a repeat of global trends where demand for weight-loss drugs rapidly outpaces regulatory oversight.

They emphasised that while GLP-1 drugs may offer important therapeutic benefits for carefully selected patients with obesity and diabetes, their indiscriminate use without medical evaluation could create a new public health challenge involving medication misuse, adverse drug reactions, and unethical commercial promotion.